GlaxoSmithKline plc: Will Its Enhanced Focus on Immunotherapy and Oncology Yield Dividends?

GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion. Highlighting the company’s effective operational execution and a diverse portfolio, GSK’s core operating profit improved by 21% to GBP 2.5 billion, and core earnings per share increased by 17% to 43.4p, all figures adjusted to exclude contributions from COVID solutions. This demonstrates GSK’s ability to achieve profitable growth driven by both its longstanding and newly launched products.